Utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening in patients with acute myeloid leukemia (AML).
Millicynth TalagtagTwisha S PatelGianni B ScappaticciAnthony J PerissinottiAllison J SchepersLindsay A PettyKristen M PettitPatrick W BurkeDale L BixbyBernard L MariniPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2021)
Given the low prevalence, empiric use of anti-MRSA therapy in those AML and HCT patients with pneumonia may not be warranted in clinically stable patients. For patients in whom empiric anti-MRSA antibiotics are initiated, nasal screening for MRSA may be utilized to de-escalate anti-MRSA antibiotics in patients with AML with or without HCT.
Keyphrases
- methicillin resistant staphylococcus aureus
- acute myeloid leukemia
- staphylococcus aureus
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- allogeneic hematopoietic stem cell transplantation
- peritoneal dialysis
- stem cells
- patient reported outcomes
- bone marrow
- mesenchymal stem cells
- cell therapy
- pi k akt